Glaxo Group Limited

Stephen Anthony Burbidge

Jonathan Henry Ellis

Volker Germaschewski

Susannah Karen Ford

Peter Ernest Soden

Umesh Kumar

Karen Louise Philpott

Ian Richard Catchpole

Susannah K Ford

Antibodies that bind human &#x3b2;-amyloid peptide, methods of treating diseases or disorders characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.

Antibodies

The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and &#x3b2;-amyloid dependent cataract formation, with antigen binding proteins that bind &#x3b2;-amyloid peptide and in particular human &#x3b2;-amyloid peptide.

Antigen binding proteins

Antibodies that bind human &#x3b2;-amyloid peptide, methods of treating diseases or disorders characterised by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.

Antibodies against amyloid-&#x3b2; peptide

Growing community of inventors

Harlow, United Kingdom

Stephen Anthony Burbidge